CD44V6、NM23/NDPK在非小细胞肺癌中的表达与转移及预后关系的研究

目的探讨非小细胞肺癌(NSCLC)中CD44V6及NM23/NDPK的表达及其在NSCLC发生、转移以及预后中的意义。方法采用S-P免疫组化染色技术,检测69例NSCLC中CD44V6及NM23/NDPK的表达情况。结果肺癌原发灶CD44V6阳性表达率与NSCLC淋巴结转移及临床分期呈正相关(P<0.05,P<0.01),NM23/NDPK阳性表达率与NSCLC淋巴结转移及临床分期呈负相关(P<0.05),CD44V6及NM23/NDPK的表达与患者的生存率有关(P<0.05),但与组织学分级及分化程度无关。CD44V6及NM23/NDPK在肺癌中的表达呈明显负相关(P<0.01)。结论对NSCLC进行CD44V6及NM23/NDPK的检测,有助于预测NSCLC进展程度和淋巴结转移,以及评估NSCLC患者的预后。

Expression of CD44V6 and NM23/NDPK in non-small-cell lung cancer

Objective To explore the significance of the expression of CD44V6 and NM23/NDPK in the carcinogenesis, metastasis and prognosis of NSCLC. Methods The expression of CD44V6 and NM23/NDPK were immunohistchemically detected with S-P methods in 69 NSCLC. Results The presence of CD44V6 and NM23/NDPK were correlated with the lymph node involvement ratio and related with the TNM classification, and not with the tissue classification and degree. The positive rate of CD44V6 was higher in positive lymph node status than in negative lymph node status (P<0.05), whereas the positive rate of NM23/NDPK was lower in positive lymph node status than in negative lymph node status (P<0.01). With the increased classification, the positive rate of CD44V6 increased (P<0.01) and the positive rate of NM23/NDPK decreased (P<0.05). The 3 year survival rate in patients with CD44V6 positive tumor and with NM23/NDPK negative tumor were lower (P<0.05). Conclusion Determination of CD44V6 and NM23/NDPK by immunohistchemistry might be useful in assessing tumor progression and lymphatic metastasis and in predicting prognosis of lung cancer.